BPC+KPV+PEA 500 References

BPC-157:

  • Staresinic M, Japjec M, Vranes H, Prtoric A, Zizek H, Krezic I, Gojkovic S, Smoday IM, Oroz K, Staresinic E, Dretar V, Yago H, Milavic M, Sikiric S, Lovric E, Batelja Vuletic L, Simeon P, Dobric I, Strbe S, Kokot A, Vlainic J, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022; 10(12):3221. https://doi.org/10.3390/biomedicines10123221
  • Seiwerth, Sven et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.” Current pharmaceutical design vol. 24,18 (2018): 1972-1989. doi:10.2174/1381612824666180712110447
  • Gwyer, Daniel et al. “Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell and tissue research vol. 377,2 (2019): 153-159. doi:10.1007/s00441-019-03016-8
  • Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010
  • Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. doi:10.2174/1570159x13666160502153022
  •  Seiwerth, S., Sikiric, P., Grabarevic, Z., Zoricic, I., Hanzevacki, M., Ljubanovic, D., … Kolega, Z. (1997). BPC 157’s effect on Healing. Journal of Physiology Paris, 91(3–5), 173–178. https://doi.org/10.1016/S0928-4257(97)89480-6

Salcaprozate sodium (SNAC):

  • Twarog, Caroline et al. “Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10).” Pharmaceutics vol. 11,2 78. 13 Feb. 2019, doi:10.3390/pharmaceutics11020078
  • Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharm Sin B. 2021 Aug;11(8):2416-2448. doi: 10.1016/j.apsb.2021.04.001. Epub 2021 Apr 29. PMID: 34522593; PMCID: PMC8424290.
  • Aroda, V.R., Blonde, L. & Pratley, R.E. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord 23, 979–994 (2022). https://doi.org/10.1007/s11154-022-09735-8

KPV  (Lysine-Proline-Valine):

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.026.
  2. Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.Mol Ther. 2017;25(7):1628-1640. doi:10.1016/j.ymthe.2016.11.020
  3. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334
  4. Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. doi:10.1016/j.jcmgh.2016.01.006
  5. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.J Pharmacol Exp Ther. 2003;306(2):631-637. doi:10.1124/jpet.103.051623

Palmitoylethanolamide (PEA):

  • Clayton, Paul et al. “Palmitoylethanolamide: A Natural Compound for Health Management.” International journal of molecular sciences vol. 22,10 5305. 18 May. 2021, doi:10.3390/ijms22105305
  • Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111/bcp.13020. Epub 2016 Jun 29. PMID: 27220803; PMCID: PMC5094513.
  • Paladini, Antonella et al. “Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis.” Pain physician vol. 19,2 (2016): 11-24.
  • Brugnatelli V, Turco F, Freo U, Zanette G. Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment. Front Neurosci. 2020 Apr 21;14:371. doi: 10.3389/fnins.2020.00371. PMID: 32372912; PMCID: PMC7186328.